Análise de eficácia de acordo com valores de TMB no CheckMate 9LA

O tumor mutation burden (TMB) está potencialmente associado à eficácia clínica dos inibidores de correceptores imunes. Durante o ELCC 2022, foram apresentados os dados de eficácia da combinação de nivolumabe + ipilimumabe + quimioterapia segundo os valores de TMB tanto do tecido tumoral quanto do sangue dos pacientes.

Caminhos da Matemática: História, Educação e Aplicações

Ebook Livro BEM PDF, PDF, Câncer

Arquivos Câncer de pulmão - Página 11 de 29 - Oncologia Brasil

Ana Moreno (@superanitamix) / X

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations - ScienceDirect

Arquivo de GBCP - GBCP

Ana Moreno (@superanitamix) / X

Arquivo de GBCP - GBCP

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - The Lancet Oncology

Biomarcadores predictivos de respuesta a los inhibidores de los puntos de control inmunitario

ESMO 2022 on the CheckMate 9LA Study Results: Clinical Outcomes in Patients With Tumor PD-L1<1% With 1L Nivo + Ipi + 2 Cycles of Chemo vs. Chemo Alone for mNSCLC

Arquivo de GBCP - GBCP

Untitled

2021 Midyear Review: Non–Small-Cell Lung Cancer - Journal of Oncology Navigation & Survivorship

PDF) Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review